Study startup is already a challenging process, with researchers juggling study activation goals, accrual rates, and endpoints. Why add the complication of IBC reviews that take more than a month to complete?
Advarra’s standard IBC review turnaround time is 10 business days or less. In a case study of 52 consecutive IBC submissions for NCI-designated cancer centers, we completed reviews in an average of 6.5 business days. Across 65 COVID-19 trials, we completed reviews in an average of 4.1 business days.
The less time it takes to complete IBC reviews, the more attractive sites are to industry sponsors and CROs—and the faster patients can gain access to clinical trials.